Trump Admin Negotiating to Lower Cost of Ozempic to $150

The Trump administration is in negotiations to obtain popular weight-loss drug Ozempic at a dramatically reduced price in the United States, according to President Donald Trump.

The drug, made by Danish manufacturer Novo Nordisk, will be sold at most-favored nation pricing, meaning the lowest price available in developed countries.

“In London, you’d buy a certain drug for $130 and even less than that … And in New York, you pay $1,300 for the same thing,” Trump said in the White House announcement.

“Now you’ll be paying … about $150 and they’ll be paying $150, so we’ll pay the same thing,” Trump said.

In a later question-and-answer exchange with reporters, Trump confirmed that he had been referring to Ozempic.

Dr. Mehmet Oz, administrator of the Centers for Medicare and Medicaid Services, immediately stepped to the microphone to clarify that negotiations for Ozempic and similar medications had not been completed. “We’re going to be rolling these out over time,” Oz told reporters.

Asked if there was a timeline for negotiations, Trump said, “No, but I think those are going to come down pretty fast.”

“The president will be happy with the result,” Oz added. “And until he is, we’re not going to close those negotiations.”

The exchange with reporters came after the announcement of a deal with EMD Serono to offer all of its fertility medications at most-favored nation pricing in the United States.

Trump issued the Most Favored Nation Prescription Drug Pricing executive order on May 12, asking drugmakers to offer their lowest prices on a slate of drugs in the United States.

Prescription drug prices are higher in the United States than anywhere else in the world, more than twice as much on average, according to a 2024 report from the Department of Health and Human Services. For the most expensive medications, the disparity is even greater.

In his May 12 executive order, Trump asked drug makers to voluntarily offer the lowest price to U.S. customers. If they did not, Trump said he would “take additional aggressive action.”

Unsatisfied with the response from drug makers, the president repeated the call in a July letter to CEOs of 17 U.S. pharmaceutical companies.

Since then, the White House has announced agreements on most-favored nation pricing with Pfizer, Amgen, and AstraZeneca.

Discounted drugs will be available to consumers through TrumpRx.gov, a prescription drug clearinghouse planned for early 2026, according to the White House.